President's Report 2004

ACP Sciences for Life

President’s Report 2004

“There is a single light of science, and to brighten it anywhere is to brighten it everywhere.”

—Isaac Asimov (author, chemist, educator; 1920-1992)

ACP/President’s Message

Sciences for Life At the beginning, I will give you a sneak preview of the end.

“The important thing,” Albert Einstein reminds us in the valedictory we have chosen for our first annual President’s Report, “is not to stop questioning.”

From the prescient and, especially for ACP, very timely words of Isaac Asimov on the facing page through Einstein’s closing thoughts, you will find highlights of the outstanding research and scholarly activity at ACP in 2003-04. We dedicate ourselves to enriching science on our campus, while incorporating a broad spectrum of scholarly endeavors. Our purpose is to contribute to the pursuit of scientific, pharmaceutical and ACP President James J. Gozzo, Ph.D. (above) discusses angiogenesis in a

humanistic exploration, thereby expanding our academic environment and brightening the light of science … Sciences for Life.

It has been an exciting period at ACP. We welcomed the debut of the Pharmaceutical Research Institute in the former Bender Hygienic Laboratory building on the south edge of campus. Related to PRI, we were gratified

Pharmaceutical Research

to receive a $1 million award under the New York State Health Care Reform Act – $750,000 through the Senate and $250,000 through the Assembly – to help develop a preformulation

Institute laboratory. Angiogenesis, the formation of new blood vessels, is central

and stability testing facility we plan to debut in 2005.

We triumphed in the largest research grant in our history, Dr. Robert Levin’s $1.15 million award from the National Institutes of Health, as well as a $500,000 research award from the New York State Department of Health for a team from our Department of Pharmacy Practice, led by Dean Mary H. Andritz, Pharm.D.

to ongoing research activities at PRI as well as Dr. Gozzo's work in organ

We have expanded our Office of Research Administration into a comprehensive Office of Grants Administration to better assist our faculty in developing new funding sources that will allow us to continue to expand our research activities.

We take great pride in our dynamic progress in research and the exceptional work of our faculty and students, and we are proud of the new discoveries, new ideas and new directions

tissue transplantation.

these efforts bring to ACP. We are preparing our campus and our students to be leaders in the new era of health care that dawned with the sequencing of the genomic code at the turn of this century.

Research and scholarly activity are vital and will remain at the forefront of all our academic pursuits, driving the spirit of inquiry and innovation on our campus.

James J. Gozzo, Ph.D. President

1 / PRESIDENT’S REPORT 2004

Sciences for ...

Exploration From the bench to the bedside.

That is the long, complex journey prescription medications must follow before they can serve their intended purpose. That, too, is the pathway ACP has opened to students and faculty through the Pharmaceutical Research Institute.

“There are no such things as incurables; there are only things for which man has not found a cure.”

—Bernard M. Baruch (financier, statesman; 1870-1965)

PRESIDENT’S REPORT 2004 / 2

PRI-Albany is dedicated to cutting-edge research, pharmaceutical services and education. The Institute works to develop partnerships with pharmaceutical and biotechnology companies, and academic and research centers in New York State, nationally and worldwide.

Under the direction of Shaker A. Mousa, Ph.D., a senior research scientist and fellow at DuPont Pharmaceuticals Co. for nearly two decades, PRI-Albany strives to enrich and advance pharmaceutical education by providing hands-on access to the full spectrum of drug development.

Pre-clinical testing. Clinical trials. Drug formulation. Research to develop novel medicines for angiogenesis, thrombosis and vascular disorders.

Dr. Mousa’s highly successful career in industry has provided an exceptional real-world perspective at ACP. His unique elective course in drug discovery and development, offered for the first time in the Spring 2004 semester, brought to campus myriad industry experts illuminating each careful step of the process.

From the bench to the bedside.

ACP/Pharmaceutical Research institute

Dr. Shaker Mousa (right), Director of the Pharmaceutical Research Institute, seeks pharmaceutical methods to inhibit angiogenesis for the treatment of cancer and macular degeneration.

Blood, sweat and years The lifeblood of Shaker Mousa’s research is blood itself.

How it travels. How to regulate it. The vessels in which it moves. The diseases that can be better managed and eradicated through its controlled ebb and flow.

These are among the questions Dr. Mousa (Ph.D., The Ohio State University) has investigated for a quarter century, dedicating his distinguished research career to the study of angiogenesis, thrombosis and vascular disorders.

Dr. Mousa came to ACP in 2002 from DuPont Pharmaceuticals Co. As Director of the College’s Pharmaceutical Research Institute, he is charged with the Institute’s development, central to ACP’s ongoing academic and research growth, while simultaneously continuing a passionate pursuit of his research interests.

Among his primary work, Dr. Mousa is seeking pharmaceutical methods to inhibit angiogenesis – the formation of new blood vessels – for the treatment of cancer and macular degeneration. The latter disease, an eye affliction caused by too much blood flow to the back of the eye, is becoming more prevalent in America as the population ages.

“Regulation of blood vessel growth underlies a wide spectrum of biological processes,” Dr. Mousa said.

Based on Dr. Mousa’s patents – he has more than 100 in the United States and foreign countries – ACP has formed Angiopharma Inc., a company that will focus on drug discovery and development. One goal will be to develop nanomedicines – drugs encapsulated inside minute particles in the blood that can treat specific targets with a slow release of medication over time.

Interestingly, this harkens back to the work of a 1931 ACP graduate: Dr. Rudolph H. Blythe, whose innovative research led to the invention of time-release capsules.

“These modalities will aid in disease definition and in monitoring the influence of therapy in disease progression,” Dr. Mousa said.

3 / PRESIDENT’S REPORT 2004

Publications Shaker A. Mousa Mousa SA, Mousa AS. Angiogenesis inhibitors: current and future directions. Current Pharmaceutical Design 10(1):1-9, 2004.

Smallheer JM, Weigelt CA, Woerner FJ, Wells JS, Daneker WF, Mousa SA, Wexler RR, Jadhav PK. Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds. Bioorganic & Medicinal Chemistry Letters 14(2):383-387, 2004.

Mousa, SA: Are Low Molecular weight Heparin the same/? In Vossoughi J, et al (eds): Thrombosis Research and treatment: from Bench to bedside. Washington, D.C: Medical and Engineering Publishers, Inc., 279-286, 2004.

Abdel-Razeq H, Qari M, Kristensen J, Alizeidah H, Al-Sayegh F, Marashi M, Alzeer A, Al-Amoudi O, Qutub H, Al-Humiadi AA, Husted S, Mousa SA. GCC Thrombosis Study Group: Guidelines for diagnosis and treatment of deep venous thrombosis and pulmonary embolism. Methods in Molecular Medicine 93:267-292, 2004.

Mousa SA. Oral thrombin inhibitor Ximelagatran.

Methods in Molecular Medicine 93:247-251, 2004.

Mousa SA. Arixtra (fondaparinux sodium).

Methods in Molecular Medicine 93:239-246, 2004.

Mousa SA. Cell adhesion molecules: Potential therapeutic and diagnostic implications. Methods in Molecular Medicine 93:157-174, 2004.

Mousa SA, Fareed J, Iqbal O, Kaiser B. Tissue factor pathway inhibitor in thrombosis and beyond.

Methods in Molecular Medicine 93:133-155, 2004.

Mousa SA. Tissue factor/VIIa in thrombosis and cancer. Methods in Molecular Medicine 93:119132, 2004.

Mousa SA. Are low molecular weight heparins the same? Methods in Molecular Medicine 93:4959, 2004.

Mousa SA. Heparin and low molecular weight heparin in thrombosis, cancer and inflammatory diseases. Methods in Molecular Medicine 93:3548, 2004.

McCarty OJ, Abulencia JP, Mousa SA, Konstantopoulos K. Evaluation of platelet antagonists in an in vitro flow models of thrombosis. Methods in Molecular Medicine 93:21-34, 2004.

Iqbal O, Mousa SA. Antiplatelet, anticoagulant and thrombolytic drug interactions. Methods in Molecular Medicine 93:9-20, 2004.

PRESIDENT’S REPORT 2004 / 4

Mousa SA. Highlights of latest advances in antithrombotics. Methods in Molecular Medicine 93:1-7, 2004.

Colman RW, Pixley RA, Sainz IM, Song, JS, Isordia-Salas J, Mohamed S, Powell J, Mousa SA. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecularweight kininogen. Journal of Thrombosis and Haemostasis 1(1):164-173, 2003.

Mousa SA. Alpha v vitronectin receptors in vascular-mediated disorders. Medical Research Review 23(2):190-199, 2003.

Marcinkiewicz C, Weinreb PH, Calvete JJ, Kisiel DJ, Mousa SA, Tuszynski JP, Lobb RR. Obtustatin, a potent selective inhibitor of alpha1/beta1 integrin in vitro and angiogenesis in vivo. Cancer Research 63:2020-2023, 2003.

Mousa SA. Antithrombotics in thrombosis and cancer. Expert Review of Cardiovascular Therapy 1(2):89-96, 2003.

Amirkhosravi A, Mousa SA, Amaya M, Frances JL. Antimetastatic effect of tinzaparin, a low molecular weight heparin. Journal of Thrombosis and Haemostasis 1(9):1972-1976, 2003.

Mousa SA, Bozarth JM, Barrett JS. Pharmacodynamic properties of the low molecular weight heparin, tinzaparin: effect of molecular weight distribution on plasma tissue factor pathway inhibitor in healthy human subjects. Journal of Clinical Pharmacology Therapeutics 43(7):727-734, 2003.

ACP/Pharmaceutical Research Institute

Amirkhosravi A, Mousa SA, Amaya M, Frances JL. Inhibition of tumor cell-induced platelet aggregation and lung metastasis by the oral GPIIb/IIIa antagonist XV454. Journal of Thrombosis and Haemostasis 90(3):549-554, 2003.

Project: Effect of Pentasaccharide versus LMWH on wound healing.

Sponsor: Sanofi Current period: $72,000 Project period: $72,000

Naik MU, Mousa SA, Parkos CA, Naik UP. Signaling through JAM-1 and alphav-beta3 is required for the angiogenic action of bFGF: dissociation of the JAM-1 and alphav-beta3 complex. Blood 102:2108-2114, 2003.

Project: Effect of COX2 inhibitor in combination with Pentasaccharide versus LMWH on wound healing.

Sponsor: Sanofi Current period: $34,000 Project period: $34,000

Mousa SA. Antiplatelet therapies: Platelet GPIIb/IIIa antagonists and beyond. Current Pharmaceutical Design 9(28):2317-2322, 2003.

Qari M, Adbel-Razeq H, Alzeer A, Alizadeh H, Kristensen J, Al-Sayegh F, Qutub H, Marashi M, Husted S, Mousa SA. Recent advances in the diagnosis and treatment of deep vein thrombosis: A regional consensus. Current Opinion in Investigational Drugs 4(3):309-315, 2003.

Mousa SA. Anti-integrin as a potential therapeutic target in angiogenesis. In Vossoughi J, et al (eds): Angiogenesis: Bench to Bedside. Washington, D.C: Medical and Engineering Publishers, Inc., 331-348, 2003.

Project: Cancer-thrombosis-inflammation biomarkers in adenocarcinoma patients.

Sponsor: Pharmion Inc. Current period: $20,000 Project period: $20,000 Project: Proteomics in pancreatic cancer patients on Tinzaparin.

Sponsor: Pharmion Inc. Current period: $25,000 Project period: $25,000 Project: Publication grant.

Sponsor: Pharmion Inc. Current period: $20,000 Project period: $20,000

Grants/Funding Shaker A. Mousa Project: Support of a preformulation and stability testing lab.

Sponsor: New York State Health Care Reform Act Current period: $1,000,000 Project period: $1,000,000 Project: Comparative anti-thrombotic and anticancer efficacy of different LMWHs and GAGs. Sponsor: Leo Pharmaceuticals Current period: $186,000 Project period: $186,000 Project: Anti-thrombotic efficacy of the direct thrombin inhibitor Xemilegatran in aspirin, statin or GPIIb/IIIa antagonist.

Sponsor: AstraZeneca Current period: $78,000 Project period: $78,000

5 / PRESIDENT’S REPORT 2004

Sciences for ...

Discovery Science.

It is at the core of every ACP education. How the body functions. How diseases begin and grow. How medications treat and affect each and every cell within each and every one of us.

“I keep the subject constantly before me and wait till the first dawnings open little by little into the full light.”

—Sir Isaac Newton (scientist, mathematician; 1642-1727)

PRESIDENT’S REPORT 2004 / 6

Behind this fundamental principal at ACP is the faculty in our Department of Basic and Pharmaceutical Sciences. The knowledge they bring to the classroom and the laboratory every day is infused with the experience of their own research.

Cancer. Macular degeneration. Bladder dysfunction. Drug addiction.

Department faculty conduct ongoing, funded basic research projects in these areas and more. They use virtually all basic science methodologies, including whole-animal models of specific pathologies, in vitro and in situ organ and tissue preparations, cell biochemistry, metabolism, energetic and tissue culture techniques, cell biology, receptor pharmacology and second messenger systems, molecular biology, stress proteins and mitochondrial gene expression.

With these tools, they seek discoveries that not only help improve the human condition and advance medical science, but that also bring to life for our students the words and ideas they encounter throughout their academic careers.

ACP/Department of Basic and Pharmaceutical Sciences

Research with a sense of urgency

Dr. Robert Levin (above) believes elevated levels of antioxidants beginning around age 30 can delay the onset and reduce the severity of bladder dysfunction, which affects 80 percent of men over age 50.

Friends call him “Bladder Bob.” Nieces and nephews call him “Uncle Bladder Bob.” But to colleagues, he’s just Dr. Robert M. Levin, one of the world’s pre-eminent experts on the uncomfortable but very real problem of bladder dysfunction, which affects 80 percent of men over 50.

Dr. Levin (Ph.D., University of Pennsylvania) has received the largest research grant in the history of ACP, a $1.15 million, four-year award from the National Institutes of Health to continue his efforts to help minimize the discomfort and health risks of bladder dysfunction.

“The fact that the NIH has funded this project is significant because it says there is strong NIH support of research into the use of alternative therapies for obstructive bladder dysfunction,” Dr. Levin said.

Dr. Levin, a Professor in the Department of Basic and Pharmaceutical Sciences and a Pharmacologist and Senior Career Research Scientist at the Stratton VA Medical Center in Albany, will investigate the potential benefits of antioxidants in mitigating loss of bladder function.

Associate Professor Dr. Martha A. Hass (Ph.D., Rensselaer Polytechnic Institute), the Department Chair, is a co-investigator. Drs.

Levin and Hass have published a number of joint scientific articles that have formed the basis of these projects.

“Our goal is to prove that ischemia (reduced blood flow to the bladder) and reperfusion, which leads to the creation of free radicals that can damage cellular and subcellular membranes, is the major etiology of obstructive bladder dysfunction,” Dr. Levin said.

A continually enlarging prostate is an unavoidable fact of life. The prostate, genetically programmed to grow throughout a man’s life, forms a ring around the urethra.

As it grows it impedes the flow of urine.

This forces the bladder to work harder to empty, which over time causes the bladder to lose elasticity and its ability to empty efficiently and completely. This leads to more frequent urination and, in severe cases, potentially life-threatening kidney infections.

Most men will require medical attention, either surgical, pharmacological or both, depending on the severity. Dr. Levin believes exposing men to elevated levels of antioxidants beginning at about age 30 will delay the onset and reduce the severity of this condition, and that men who would have started experiencing symptoms in their 40s will not show symptoms until their 60s.

7 / PRESIDENT’S REPORT 2004

Can we beat breast cancer the same way we build strong bones?

Vitamin D. It’s not just for strong bones anymore.

One of the most widely recognized vitamins, we read about vitamin D every time we pour a glass of milk. Our bodies produce it every time sunlight touches our skin. But scientists like Jeff Voigt are starting to believe it might have profound potential for the treatment of one of our most fearsome diseases – cancer.

Although results are as yet generally inconclusive, previous research by Dr. Voigt (Ph.D., University of Iowa) and others has provided promising data that suggests a possible connection between increased levels of vitamin D and decreased incidence of some cancers.

In particular, Dr. Voigt is investigating whether increased levels of vitamin D can kill breast cancer cells. In research funded

by ACP’s intramural Rudolph Blythe Research Grant, Dr. Voigt is conducting a three-pronged project based on this basic premise.

First, he is studying whether treating breast cancer cells with vitamin D results in a decrease in the activity of AP-1, a

transcription factor involved in the regulation of a number of pathways capable of inhibiting the proliferation of breast cancer cells.

Second, he is studying whether increasing expression of the protein VDUP-1, a protein that is increased following treatment with vitamin D, inhibits activity of thioredoxin, another protein believed to be central to the proliferation of cancer cells through its effect on AP-1.

Lastly, Dr. Voigt hopes to identify whether increased VDUP-1 expression directly inhibits the activity of AP-1.

“No one has looked at the effect of vitamin D on VDUP-1,” he said. “I’m trying to define what regulates the growth of cancer cells and if vitamin D impacts the process.”

Scientists like Dr. Jeff Voigt (left) are starting to believe vitamin D might have potential for the treatment of one of our most fearsome diseases – cancer.

PRESIDENT’S REPORT 2004 / 8

ACP/Department of Basic and Pharmaceutical Sciences

Publications Howard Colby Colby HD, Longhurst PA, Burczynski JM, Hayes JR, Yuan BB and Voigt JV. Downregulation of CYP2D16 by ACTH in the guinea pig adrenal cortex: Time course, reversibility and mechanism of action. Pharmacology 67:121-127, 2003.

Martha A. Hass Hass MA and Levin RM. The role of lipids and lipid metabolites in urinary bladder dysfunction induced by partial outlet obstruction. Bladder Disease: Research Concepts and Applications (Anthony Atala and Debra Slade, eds), Advances in Experimental Medicine and Biology, Kluwer Academic/Plenum Publishers, NY:217-238, 2003.

Jan Jarvis Jarvis J and Moon DG. Calculus for Biomedical Students, Xanadu Publishers, Norcross, Ga., 2004 (revised).

Robert M. Levin Malkowicz SB, Liu SP, Broderick GA, Wein AJ, Kennedy AR and Levin RM. The effect of the BowmanBirk inhibitor (a soy protein) on in vitro bladder neck/urethral and penile corporal smooth muscle activity. Neurourology and Urodynamics 221:54-57, 2003.

Matsumoto S., Kogan BA, Levin RM, Howard PS and Macarak EJ. Response of the fetal sheep bladder to urinary diversion. The Journal of Urology 169:735-739, 2003.

Levin RM, O’Connor LJ, Leggett RE, Whitbeck C and Chichester P. Focal hypoxia of the obstructed rabbit bladder wall correlates with intermediate decompensation. Neurourology and Urodynamcis 22:156-163, 2003.

Matsumoto S, Leggett RE and Levin RM. The effect of vitamin E on the response of rabbit bladder smooth muscle to hydrogen peroxide. Molecular and Cellular Biochemistry 254:347-351, 2003.

Penelope A. Longhurst Longhurst PA, Levendusky MC and Bezuijen MW. Diabetes mellitus increases the rate of development of decompensation in rats with outlet obstruction. The Journal of Urology 171:933-937, 2004.

Chou EC, Capello SA, Levin RM and Longhurst PA. Excitatory alpha1-adrenergic receptors predominate over inhibitory beta-receptors in rabbit dorsal detrusor. The Journal of Urology 170:2503-2507, 2003.

Bezuijen MW, Levendusky MC and Longhurst PA. Functional response of bladder strips from streptozotocin diabetic rats depends on bladder mass.

The Journal of Urology 169:2397-2401, 2003.

Longhurst PA. Functional development of the rat urinary bladder after pre- or postpubertal castration. Pharmacology 67:72-82, 2003.

Levin RM, Borow A, Levin SS and Haugaard N. Effect of DHLA on the response of isolated rat urinary bladder to repetitive field stimulation. Cell and Molecular Biology 246:129-135, 2003.

Levin RM, Whitbeck C, Leggett RE, Borow A, Burden O and Leggett R. Effectiveness of vaginally administered oxybutynin on bladder function and response to acetylcholine. Urology 61:1273-1277, 2003.

Aikawa K, Sugino T, Matsumoto S, Chichester P, Whitbeck C and Levin RM. The effect of ovariectomy and estradiol on rabbit bladder smooth muscle contraction and morphology, The Journal of Urology 634-637, 2003.

Aikawa K, Leggett RE and Levin RM. Effect of age on hydrogen peroxide-mediated contraction damage in the male rat bladder. The Journal of Urology 170:2082-2085, 2003.

Bratslavsky G, Kogan BA, Matsumoto S, Aslan AR and Levin RM. Reperfusion injury of the rat bladder is worse than ischemia. The Journal of Urology 170:2086-2090, 2003.

Matsumoto S, Chichester P, Kogan BA and Levin RM. The structural and vascular response of normal and obstructed rabbit whole bladders to distension. Urology 62:1129-1133, 2003.

David W. Clarke Clarke DW. Assessing the efectiveness of Webbased experiments within a general chemistry lab.

American Association of Colleges of Pharmacy, Minneapolis, Minn., July 2003.

Clarke DW. Use of residual magnevist as a contrast agent in intrarticular MRI. Northeast Regional Meeting of the American Chemical Society, Saratoga Springs, N.Y., June 2003.

Martha A. Hass Hass MA, Leonova E and Levin RM. Effects of estradiol on urothelial glycosaminoglycans. Interstial Cystitis Association Meeting, Alexandria, Va., October 2003.

William R. Millington Vance MA, Crandall A, Moore J and Millington WR. Selling of alternative medicines and the pharmacy profession. Inter-American Conference on Pharmacy and Health Sciences, Havana, Cuba, March 2003.

William R. Millington Gurun MS, Millington WR and Ulus IH. Choline potentiates the pressor response evoked by glycyl-glutamine or naloxone in hemorrhaged rats.

Clinical and Experimental Pharmacology and Physiology 30:640-642, 2003.

Cavun S, Millington WR and Ulus IH. Evidence that the ventromedial hypothalamus region mediates the hypotension and bradycardia evoked by severe hemorrhage. Turkish Neuroscience Society, Bursa, Turkey, June 2003.

Gail G. Snitkoff Goodman-Snitkoff, G. Immunology, Chapter 10, Comprehensive Pharmacy Review. Fifth edition, L. Shargel, editor, 2003.

Cavun S, Levendusky M, Kidney JL and Millington WR. Inhibition of morphine-induced preference conditioning by glycyl-glutamine, an endogenous peptide derived from e-endorphin. International Narcotics Research Conference, Perignon, France, July 2003.

Grants Buttyan R, Chichester P, Matsumoto S, Stisser B, Ghafar MA and Levin RM. Acute intravesical infusion of a cobalt solution stimulates a hypoxiaresponse, growth and angiogenesis in the rat bladder. The Journal of Urology 169:2402-2406, 2003.

Presentations/Abstracts

Robert M. Levin Project: Ischemic etiology of obstructive bladder dysfunction.

Sponsor: National Institutes of Health Current period: $288,570 Project period (2004-08): $1,154,280 Project: Biomarkers.

Sponsor: Veterans Administration Merit Review Grant Current period: $140,000 Project period (2001-06): $840,000 Project: Protective effect of grape suspensions on obstructive bladder dysfunction.

Sponsor: California Table Grape Commission Current period: $25,000 Project period: $25,000 Project: Role of nitric oxide on the acute response of the rabbit to partial outlet obstruction.

Sponsor: Yamaneuchi USA Research Foundation Current period: $30,000 Project period: $30,000 William R. Millington Project: Neurobiology of hemorrhage.

Sponsor: Office of Naval Research Project period (2001-03): $233,687

Cavun S, Ulus IH and Millington WR. Glycyl-L-glutamine inhibits morphine tolerance, dependence and withdrawal. International Narcotics Research Conference, Perignon, France, July 2003.

Matsumoto S, Goto Y, Kogan BA, Longhurst PA, Levin RM and Millington WR. Opiod receptors in the mid-brain periaqueductal gray region regulate volume-evoked micturition. 33rd International Continence Society, Florence, Italy, October 2003.

Dudley G. Moon Quiles VA, Markham A, Levin RM and Moon DG. 45 days in Japan: Students’ personal experiences of a summer research fellowship in a Japanese pharmaceutical company. 25th Annual Undergraduate Research Symposium, West Virginia University, October 2003.

Adwoa O. Nornoo Nornoo AO. The influence of formulation characteristics on the in situ permeability of low solubility and/or low permeability anticancer agents in microemulsions for oral administration. Model compound: Paclitaxel. Annual Meeting of the American Association of Pharmaceutical Scientists, Salt Lake City, Utah, November 2003.

Bold – Denotes ACP faculty collaborating on a project.

Jean Taylor Project: Microscope projection and computer capture system.

Sponsor: The Bender Scientific Fund of The Community Foundation for the Capital Region Current period: $10,000 Project period: $10,000

9 / PRESIDENT’S REPORT 2004

Sciences for ...

Caring Managing disease states. Dispensing medications and information. Consulting with patients and their physicians.

Improving, extending and saving lives.

The practice of pharmacy.

“... the great need is to look at pharmacy from the point of view of the patient – that is, unless we come up with something which deals with people, not pharmacists, not research laboratories, not physicians, not nurses, not drug store proprietors, not the system, et cetera – we really have not added much ...”

—Dr. John S. Millis (physicist, mathematician, educator; 1903-1988)

PRESIDENT’S REPORT 2004 / 10

This has been ACP’s primary mission since our inception in 1881, and it will remain a central, vital purpose as we expand our academic breadth and degree offerings.

The number of prescription drugs available in America has mushroomed 20-fold since 1970. It will continue to grow exponentially as scientific discovery opens new horizons in medicine.

Armed with these increasingly effective and targeted medicines, and equipped with the highest level of pharmaceutical expertise available to health care practitioners, pharmacists in a wide variety of community, clinical and industry settings will be increasingly critical to the science of caring for society’s well being.

The faculty in our Department of Pharmacy Practice are active in research helping to document the human and financial benefits of this new paradigm. The cost of drug therapy misadventures. The need for, and value of, improved pharmaceutical care. The clinical and economic impact of pharmacists dedicated to providing that care.

The invaluable practice of pharmacy.

ACP/Department of Pharmacy Practice

A plan to improve adult care In a widely cited study published in 1995, J. Lyle Bootman and Jeffrey A. Johnson evaluated the cost of medication-related problems among residents of nursing facilities.

This population is particularly vulnerable due to advanced age, frail health, multiple chronic conditions and polypharmacy.

Drs. Johnson and Bootman, of The University of Arizona College of Pharmacy, found that in this population for every dollar spent on medication costs, two dollars are spent on medication-related problems.

ACP faculty, led by Dean Mary H. Andritz, now are out to demonstrate how effective pharmacists can be in reducing these costs and improving quality of life in adult care facilities.

Funded by a two-year, $500,000 grant from the New York State Department of Health and working together with The Sage Colleges School of Nursing, ACP faculty are seeking to improve medication management and reduce medication errors by implementing a pharmacist intervention program similar to that in effect for long-term care facilities.

Dr. Andritz (Pharm.D., State University of New York at Buffalo) is joined on the project

by Department of Pharmacy Practice faculty Drs. Laurie Briceland (Pharm.D., State University of New York at Buffalo), Michael Brodeur (Pharm.D., St. John’s University) and Nancy Waite (Pharm.D., Wayne State University).

The program will include review of residents’ medication needs and intervention to resolve medication-related issues. The implementation of similar programs, in which pharmacists take responsibility for the drug therapy outcomes of patients, has proved effective in a variety of other clinical practice settings, including generalized hospital patient populations, critical settings, home care settings and assisted living facilities.

This unique partnership offers an opportunity for ACP to play a pivotal role in developing a model that can be replicated across the state to improve the care in all adult care facilities.

ACP faculty, led by Dean Mary H. Andritz (right), hope to demonstrate how effective pharmacists can be in reducing costs and medication-related problems in adult care facilities.

11 / PRESIDENT’S REPORT 2004

House calls for healthier, longer lives

Dr. Darren Triller (above) believes his findings could help bring about a fundamental change in health care delivery in the United States.

This medical professional makes house calls.

Dr. Darren Triller (Pharm.D., ACP), has been working for the past five years on a research to establish statistical proof of what he believes is clear through anecdotal evidence – dramatic cost and quality-of-life benefits of home visits by a pharmacist.

“There is a lot of literature out there that says pharmacy care is good, and intellectually you would say it is,” said Dr. Triller, an Assistant Professor in the Department of Pharmacy Practice. “But the rub is getting someone to pay for it.”

This innovative research project is in conjunction with the Eddy Visiting Nurses Association and funded by a $273,621 grant from The Jacob and Valeria Langeloth Foundation.

It pilots a new care model for heart failure patients recovering at home, supplementing home nursing care with the services of a clinical pharmacist.

Dr. Triller or Stephen Clause, Pharm.D., a research fellow hired through the Langeloth grant, visit recovering heart patients at home and evaluate the appropriateness of the drugs prescribed, assess complex medication schedules and provide counseling.

With data collection to be completed by the fall, Dr. Triller believes his findings could help bring about a fundamental change in health care delivery. He hopes to show a 40 percent reduction in rehospitalizations and death at the six-month followup. He also believes patients will demonstrate improved quality of life and reduced drug-related problems, and that there also will be an overall reduction in health care costs by providing services in the home rather than in the hospital.

Dr. Triller’s research already has proved valuable. The Eddy VNA has agreed to cofund a post-doctoral resident to expand pharmacy services to the more than 1,000 patients it serves.

“You go to patients’ homes all the time and there are always problems,” Dr. Triller said. “You know there’s a value to what you’re doing because you see it.”

Expanding a pharmacist’s role Pharmacists long have advocated for an expanded role in the delivery of health care, understanding intuitively how valuable their knowledge and experience can be.

Jennifer Cerulli is out to prove it.

Looking beyond the traditional role of the pharmacist, Dr. Cerulli (Pharm.D., ACP) focuses her research on quantifying the impact a community pharmacist can have as a patient educator. Among her objectives is to define a value for such services that will help lead to new funding sources and

PRESIDENT’S REPORT 2004 / 12

legislation to allow patients to receive greater health benefits from their visit to the local pharmacy.

In two studies funded by Wyeth, Dr. Cerulli, an Associate Professor in the Department of Pharmacy Practice and a member of the department’s Community Pharmacy Practice Group, has studied the

ACP/Department of Pharmacy Practice

Helping manage kidney disease George Bailie has been stalking a killer most of his adult life.

Kidney disease is the killer: some 75,000 patients on dialysis die annually in the United States. More than 20 million Americans have kidney disease – about 1 in 9 adults.

Dr. Bailie (Pharm.D., University of Minnesota; Ph.D., University of Wales) has been involved for 20 years in pharmacokinetic and other studies, seeking new and better dosing regimens to manage the disease, focusing on end-stage kidney failure and dialysis patients.

One tricky variable is that these patients process medications at widely varying rates because of their malfunctioning kidneys. Dr. Bailie seeks to shed light on this largely unknown and potentially deadly fact.

“Most people who are involved in nephrology research are looking at the disease process,” said Dr. Bailie, a Professor in the Department of Pharmacy Practice.

“There has been very little research on the treatment of the disease or on the effects of the disease on drug requirements.”

A member of the Kidney Disease Outcome Quality Initiative Advisory Board, Dr. Bailie’s current work is in connection with a

large University of Michigan project, the Dialysis Outcomes and Proactive Patterns Study, or DOPPS. The study began in 1996 and involves seven countries, including the United States.

Funded through a renewed two-year, $145,000 grant from the Renal Research Institute, Dr. Bailie is studying prescription patterns of medications in dialysis patients and determining the outcomes of treatment.

His initial findings on analgesic use will be published this year in Kidney International, the premier nephrology journal. Another focus has been the use of statins to treat blood cholesterol in dialysis patients at high risk of heart disease.

Dr. Bailie’s dedication also has spread at ACP. Drs. Darren Grabe and Rowland Elwell (both Pharm.D., ACP), department colleagues and former research fellows with Dr. Bailie, focus their research on kidney disease.

benefits of performing bone mineral density screenings and providing menopause counseling to women.

By performing bone mineral density screenings, osteoporosis was detected and treated in patients in whom it otherwise would have gone undiagnosed. Her findings were published in the March/April 2004 Journal of the American Pharmacists Association (co-authored by ACP colleague Mario M. Zeolla, Pharm.D.).

Dr. Cerulli also found that menopause counseling helped women gain a more complete understanding of their evolving and

often-complex health needs. This allowed women to be more prepared to discuss treatment options with their physicians.

“An educated pharmacist can be a valuable resource to patients and their health care team,” she said.

Dr. George Bailie (above) seeks new and better dosing regimens to manage kidney disease, focusing on end-stage kidney failure and dialysis patients.

Dr. Jennifer Cerulli (facing page) is looking beyond the traditional role of the pharmacist to quantify the impact a community pharmacist can have as a patient educator.

13 / PRESIDENT’S REPORT 2004

Publications Edward C. Allie Allie EC, Kane MP, Busch RS, Bakst G and Hamilton RA. Orlistat in obese patients with type 2 diabetes: A retrospective assessment of weight loss and metabolic effects. Hospital Pharmacist 39:3742, 2004.

Elwell RJ and Bailie GR. Influence of classroom and clinical experience on the ethical decisions made by Doctor of Pharmacy students. International Journal of Pharmacy Education [serial online] 2003;1: Available from: http://www.samford.edu/schools/pharmacy/ijpe/index.htm.

Nicole D. Allie Rojas-Fernandez CH, Eng M and Allie ND. Pharmacologic management by clinical pharmacists of behavioral and psychological sysmptoms of dementia in nursing home residents: results of a pilot study. Pharmacotherapy 23:217-221, 2003.

Elwell RJ, Spencer AP and Eisele G. Combined furosemide and albumin treatment for diureticresistant edema. The Annals of Pharmacotherapy 37, 2003: “Articles Ahead of Print” (www.theannals.com).

George R. Bailie Perlman RL, Kiser M, Finkelstein F, Eisele G, Roys E, Liu L, Burrows-Hudson S, Port F, Messana J, Bailie GR, Rajagopalan S and Saran R. The longitudinal chronic kidney disease study: A prospective cohort study of predialysis renal failure. Seminars in Dialysis 16:418-423, 2003.

Manley HJ, Bridwell DL, Elwell RJ and Bailie GR. Influence of peritoneal dialysate flow rate on the pharmacokinetics of cefazolin. Peritoneal Dialysis International 23:469-474, 2003.

Manley HJ, Bailie GR, McClaran ML and Bender WL. Gentamicin pharmacokinetics during slow daily home hemodialysis. Kidney International 63:1072-8, 2003.

John J. Farragon Faragon JJ and Lesar TS. Update on prescribing errors with HAART. The AIDS Reader 13:268-278, 2003.

Faragon JJ, Waite NM, Hobson EH, Seoldo N, VanAmburgh JA and Migden H. Improving aspirin use in a primary care diabetic population. Pharmacotherapy 23(1):73-79, 2003.

Gina D. Garrison Garrison GD, Sorum PC, Hioe W and Miller MM. High-dose versus standard-dose amoxicillin for acute otitis media. The Annals of Pharmacotherapy 38: 15-19, 2004.

Darren W. Grabe Manley H and Grabe DW. Determination of iron sucrose (Venofer) or iron dextran (DexFerrum) removal by hemodialysis: An in-vitro study. BMC Nephrology 5:1, 2004.

Robert A. Hamilton Hamilton RA, Kane MP and Demers J. ACE inhibitors and type 2 diabetic nephropathy: A meta-analysis. Pharmacotherapy 23:909-15, 2003.

Michael P. Kane Stroup J, Kane MP and Busch RS. The antilipidemic effects of ezetimibe in patients with diabetes.

Diabetes Care 26:2958-9, 2003.

Stroup J, Kane MP, Busch RS, Bakst G and Hamilton RA. The diabetes home visitation program.

American Journal of Pharmaceutical Education 67(3):1-8, 2003.

Rosenblum MS, Kane MP. Analysis of cost and utilization of health care services before and after initiation of insulin therapy in patients with Type 2 diabetes mellitus. Journal of Managed Care Pharmacy 9:309-16, 2003.

Demers J, Kane MP, Bakst G, Busch RS, Hamilton RA. Accuracy of home blood glucose monitors using forearm blood samples: FreeStyle versus One Touch Ultra. American Journal of Health-System Pharmacists 60:1130-5, 2003.

Jennifer Cerulli Cerulli J and Malone M. Using Center for the Advancement of Pharmaceutical Education (CAPE) outcome-based goals and objectives to evaluate community pharmacy advanced practice experiences. American Journal of Pharmaceutical Education 67(2);article 1, 2003.

Thomas P. Lodise Lodise TP, McKinnon PS, Swiderski L and Rybak MJ. Outcomes analysis of delayed antibiotic treatment for nosocomial staphylococcus aureus bacteremia. Clinical Infectious Diseases, June1;36(11):1418-23, 2003.

Cerulli J and Malone M. Using Center for the Advancement of Pharmaceutical Education (CAPE) outcome-based goals and objectives to evaluate community pharmacy advanced practice experiences. American Journal of Pharmaceutical Education, 2003.

Margaret Malone Malone M and Alger SA. Pharmacist intervention enhances adherence to Orlistat therapy. The Annals of Pharmacotherapy 37:1598-1602, 2003.

Online September 2003, www.theannals.com, DO1 10.1345/aph.1D183.

Rowland J. Elwell Elwell RJ, Neumann M and Bailie GR. Factors associated with long-term antibody production induced by hepatitis B vaccine in patients undergoing hemodialysis: A retrospective cohort study.

Pharmacotherapy 23(12):1558-1563, 2003.

Malone M. Altered drug disposition in obesity and following bariatric surgery. Nutrition in Clinical Practice, 2003.

Elwell RJ, Neumann M, Manley HJ, Carpentier L and Bailie GR. Hepatitis B vaccination: Addressing a drug-related problem in hemodialysis outpatients with a collaborative initiative. Nephrology Nursing Journal 30:310-313, 2003.

Elwell RJ, Manley HJ and Bailie GR. Impact of introductory pharmacy practice experience on student learning, satisfaction and clerkship site productivity: Assessment of the EPOC Program. International Journal of Pharmacy Education [serial online] 2003;1: Available from http://www.samford.edu/schools/pharmacy/ijpe/index.htm.

PRESIDENT’S REPORT 2004 / 14

Kara L. Shirley Desai H, Shirley KL, Jann MW and Strom G. Relative bioavailability study comparing sumatriptan (Imitrex‚) 50 mg oral tablet versus 50 mg extemporaneous suppository formulation. International Journal of Pharmaceutical Compounding. September/October 2003.

Kirkwood C and Shirley KL. Panic Disorder. Pharmacy Practice News. September 2003.

Shirley KL, Hon YY, Penzak SR, Lam YF, Spratlin V and Jann MW. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers. Neuropsychopharmacology March 2003 [e-pub ahead of print].

ACP/Department of Pharmacy Practice

Grants Mary H. Andritz Project: Development of an innovative, collaborative care model of medication safety and management to improve quality of life and functional status for adult care facilities residents.

Sponsor: New York State Department of Health Project partner: The Sage Colleges School of Nursing Co-investigators: Laurie L. Briceland, Michael R. Brodeur, Joan Dacher, Glenda B. Kelman, Kathleen Kennedy, Linda C, Peterson, Angelo Ruperto, Nancy M. Waite Current period: $250,000 Project period: $500,000 George R. Bailie Project: Evaluation of drug-related problems in hemodialysis: The Dialysis Outcomes and Practice Patterns (DOPPS) study.

Sponsor: Renal Research Institute, New York, N.Y., renewed funding.

Current period: $145,320 Project period: $145,320 Jennifer Cerulli Project: Increasing aspirin use in patients with diabetes.

Sponsor: The American Pharmaceutical Association Foundation, Incentive Grants for Practitioner Innovation in Pharmaceutical Care Co-investigator: Stephanie Haggerty Current period: $1,000 Project period: $1,000 Jean S. Cottrell Project: Implementing a weight-management program in a community pharmacy: Diet Busters.

Sponsor: Community Pharmacy Foundation Current period: $4,000 Project period: $4,000 Thomas P. Lodise Project: Impact of empirical antibiotic selection on outcomes of patients with community-acquired pneumonia in the New York Veterans Administration health care network.

Sponsor: Roche Pharmaceuticals Current period: $25,000 Project period: $25,000 Project: Evaluation of the clinical and economic implications of an extended infusion dosing strategy of piperacillin-tazobactam for pseudomonas aeruginosa infections. Sponsor: Society of Infectious Diseases Pharmacists.

Co-investigators: Ben Lomaestro, George Drusano Current period: $15,000 Project period: $15,000 Project: Evaluation of the clinical and economic implications of an extended infusion dosing strategy of piperacillin-tazobactam for pseudomonas aeruginosa infections.

Sponsor: Albany College of Pharmacy Co-Investigator: Ben Lomaestro Current period: $5,000 Project period: $5,000

Kara L. Shirley Project: Depression as a risk factor for worsening platelet aggregation and thrombosis in stage 5 chronic kidney disease patients on hemodialysis.

Sponsor: Pfizer Pharmaceuticals Independent Investigator Grant 2003 Co-investigator: Darren W. Grabe, Shaker A. Mousa Current period: $27,700 Project period: $56,400

Bailie GR. Issues in iron toxicity. Fresenius Medical Care North America, Jacksonville, Fla., June 2003.

Presentations/Abstracts

Bailie GR. Empiric therapy for peritonitis. Peritoneal Dialysis Symposium, National Kidney Foundation Annual Clinical Meeting, Dallas, Texas, April 2003.

Edward C. Allie Allie EC. Atypical antipsychotics and diabetes mellitus. Grand Rounds at Benedictine Hospital, Kingston, N.Y., December 2003.

Nicole D. Allie Allie ND, Brodeur MR, Strang AF and Weck MB. Tools of the trade: Focus on injection techniques.

American Society of Consultant Pharmacists Geriatrics 2003: The 25th Midyear Conference and Exhibition, Tampa, Fla., May 2003.

Allie ND, Brodeur MR, Strang AF and Weck MB. Tools of the trade: Focus on asthma and COPD. American Society of Consultant Pharmacists Geriatrics 2003: The 25th Midyear Conference and Exhibition, Tampa, Fla., May 2003.

Allie ND, Brodeur MR, Strang AF, Weck MB. Tools of the trade: Focus on diabetes. American Society of Consultant Pharmacists Geriatrics 2003: The 25th Midyear Conference and Exhibition, Tampa, Fla., May 2003.

George R. Bailie Bailie GR, Lane PL, Clark JA, Stang PE and Lane CE. Safety surveillance of intravenous iron preparations – relative rates of hypersensitivity reactions reported in the USA. Journal of the American Society of Nephrology 14:458A, 2003.

Bailie GR and Lane P. Safety surveillance of intravenous iron preparations: Relative rates of hypersensitivity reactions reported in the USA. American Society of Nephrology 36th Annual Meeting and Scientific Exposition, San Diego, Calif., November 2003.

Bailie GR. Dosing of drugs in peritoneal dialysis.

Renal Pharmacists Network of Canada, Toronto, September 2003.

Bailie GR. New bone disease and mineral metabolism clinical practice guidelines. Association of Managed Care Pharmacists, Montreal, October 2003.

Bailie GR. Treatment of anemia in CKD. CE Program, Rochester, N.Y., October 2003.

Bailie GR. Impact of new CKD clinical practice guidelines on pharmacy practice. Greater New York Health Association teleconference, July 2003.

Bailie GR. Empiric therapy for peritonitis. Nephrology Grand Rounds, Winthrop University Hospital, Mineola, N.Y., May 2003.

Bailie GR. The role of iron in managing the anemia of chronic kidney disease. Nephrology Update 2003, American Nephrology Nurses Association Annual Meeting, Green Bay, Wis., March 2003.

Bailie GR, Eisele G, Roys E, Kiser M, Finkelstein F et al. Medication use in CKD patients: Aalysis of the multicenter longitudinal CKD study. National Kidney Foundation Clinical Meetings program, Dallas, Texas, April 2003.

Laurie L. Briceland Briceland LL, Hamilton RA, Strang AF, Triller DM, Waite NM and Andritz MH. Implementation of a Coordinating Council as an academic Pharmacy Practice Department management model. American College of Clinical Pharmacy Annual Meeting, Atlanta, Ga., November 2003 [Encore].

Michael R. Brodeur Brodeur MR. Timely topics in geriatrics. American Society of Consultant Pharmacists Annual Meeting, San Antonio, Texas. November 2003.

Jennifer Cerulli Cerulli J. Current trends in hormone replacement therapy, PHARMEd CE Program, Albany, N.Y., September 2003.

Haggerty S, Cerulli J, Zeolla MM, Weck MB, Schreck J and Faragon JJ. Increasing aspirin use in diabetic patients. American Pharmacists Association 151st Annual Meeting, New Orleans, La., March 2003.

Cerulli J. Reaching beyond the bench: Impressions on academic community pharmacy practice.

Albert B. Prescott/Glaxo Smith Kline Leadership Award Lecture, American Pharmacists Association 151st Annual Meeting, New Orleans, La., March 2003.

Rowland J. Elwell Elwell RJ, Manley HJ and Bailie GR. Impact of dwell time and flow rate on ceftazidime dialysate concentration: Should APD patients switch to CAPD during peritonitis treatment? Journal of the American Society of Nephrology 14:858A, 2003.

Elwell RJ, Sy A, Mason NA and Bailie GR. Practice patterns in the care of peritoneal dialysis patients: Bone disease and phosphorus management. Journal of the American Society of Nephrology 14:859A, 2003.

15 / PRESIDENT’S REPORT 2004

Publications, continued

Elwell RJ, Sy A, Mason NA and Bailie GR. Practice patterns in the care of peritoneal dialysis patients: Anemia management. Journal of the American Society of Nephrology 14:859A, 2003.

Neuman M, Hutson J and Elwell RJ. Hypercalcemia in hemodialysis patients treated with paricalcitol. American Nephrology Nurses’ Association National Symposium, Chicago, Ill., April 2003.

Elwell RJ. Erythropoietins in chronic kidney disease: Not just for dialysis anymore. American Society of Health-System Pharmacists Midyear Clinical Meeting, New Orleans, La., December 2003.

John J. Farragon Faragon JJ, Waite NM, Hobson EH, Murphy H, Migden H. Two-year follow-up of aspirin use among an ambulatory population of patients with diabetes. American College of Clinical Pharmacy Annual Meeting, Atlanta, Ga., November 2003.

Elwell RJ, Frye RF, Ganchuk SR and Bailie GR. Pharmacokinetics of intraperitoneal cefepime in automated peritoneal dialysis. Poster presentation, ACCP Annual Meeting, Atlanta, Ga., November 2003.

Elwell RJ, Neumann, M and Bailie GR. Assessment of patient and dialysis-related factors associated with hepatitis B vaccine response. Poster presentation, American College of Clinical Pharmacy Annual Meeting, Atlanta, Ga., November 2003.

Elwell RJ. Overview of National Kidney Foundation/Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease.

American College of Clinical Pharmacy Annual Meeting, Atlanta, Ga., November 2003.

Elwell RJ. Phosphorus and calcium and their effects on your bones and cardiovascular system.

National Kidney Foundation of Northeast New York’s Patient Education Program, Albany, N.Y., April 2003.

Elwell RJ. Chronic kidney disease: Staging, complications and the pharmacist’s role. West Virginia Health-System Pharmacists and West Virginia Pharmacists Association, Charleston, W.Va., April 2003.

McKenna J, Kasper N, Ruff K, MacCracken MA and Elwell RJ. The peritoneal dialysis nurse’s role in clinical research. American Nephrology Nurses’ Association National Symposium, Chicago, Ill., April 2003.

Faragon JJ. The role of the community pharmacist in antiretroviral therapy. Pharmacists Society of the State of New York Annual Convention, Kerhonkson, N.Y., June 2003.

Malone M, Alger S and Anderson D. Medication associated with weight gain may affect outcome in a diet/exercise-based weight-loss program.

Annual Scientific Meeting, North American Association for the Study of Obesity, Fort Lauderdale, Fla., October 2003.

Malone M. Management of overweight and obese adults. 5-credit-hour Web-based Professional CE Program, Miami, Fla., July 2003.

Faragon JJ. Drug interactions associated with antiretroviral therapy. Fourth Annual HIV Clinical Care Symposium sponsored by Albany Medical College Division of HIV Medicine, Albany, N.Y., June 2003.

Malone M. Total Parenteral Nutrition (TPN) in gastrointestinal disease. Greater New York Hospital Association teleconference, June 2003.

Faragon JJ. Highly Active Anti-Retroviral Therapy (HAART) drug interactions. Infectious Diseases Grand Rounds, Upstate Medical University, Syracuse, N.Y., May 2003.

Malone M and Alger S. Gastric bypass outcome and pre-operative binge eating severity. International Conference on Eating Disorders, Denver, Col., May 2003.

Piliero PJ, Hubbard M, King J and Faragon JJ. Ultrasound associated liposuction of HIV-related buffalo humps. 10th Conference on Retroviruses and Opportunistic Infections, Boston, Mass., February 2003.

Kara L. Shirley Shirley KL. Initiating and monitoring antidepressant pharmacotherapy in primary care. Third Annual Psychiatry in Primary Care Conference, SUNY Upstate Medical Center, Syracuse N.Y., December 2003.

Gina D. Garrison Garrison GD. Update on cholesterol management.

Pharmacists Society of the State of New York Annual Convention, Kerhonkson, N.Y., June 2003.

Darren W. Grabe Grabe DW, Elwell RJ, Bailie GR and Simoni J. Comparison of oxidant stress between two IV iron formulations in hemodialysis patients. Journal of the American Society of Nephrology 14:703A, 2003.

Manley HJ and Grabe DW. Determination of iron sucrose (Venofer) or iron dextran (DexFerrum) removal by hemodialysis: An in-vitro study. Journal of the American Society of Nephrology 14:498A, 2003.

Grabe DW, Elwell RJ, Bailie GR and Simoni J. Comparison of oxidant stress between two IV iron formulations in hemodialysis patients. American Society of Nephrology 36th Annual Meeting and Scientific Exposition, San Diego, Calif., November 2003.

Thomas P. Lodise Lodise TP and McKinnon PS. Epidemiology and outcomes of bacteremic staphylococcus aureus pneumonia. 43rd Annual Interscience Conference on Antimicrobial and Chemotherapy, Chicago, Ill., September 2003.

Lodise TP. Outcomes analysis of delayed antibiotic treatment for nosocomial staphylococcus aureus bacteremia. Research Rounds, Anti-Infective Research Laboratory, Hartford Hospital, Hartford, Conn., July 2003.

PRESIDENT’S REPORT 2004 / 16

Margaret Malone Chaletsky D, Powell J, Alger-Mayer S, Malone M. Evaluation of factors which may contribute to outcome after gastric bypass surgery. New York State American College of Physicians Meeting, Syracuse, N.Y., fall 2003.

Shirley KL. Initiating and monitoring atypical antipsychotic pharmacotherapy in primary care.

Third Annual Psychiatry in Primary Care Conference, SUNY Upstate Medical Center, Syracuse N.Y., December 2003.

Titus R and Shirley KL. Aripiprazole and ziprasidone as adjuvant pharmacotherapy for the management of obesity in comorbid affective and anxiety disorders. Eastern States Conference, September 2003.

Shirley KL. Atypical antipsychotic induced weight gain and diabetes. New York State Department of Corrections, Syracuse, N.Y., August 2003.

Shirley KL. Psychiatric pharmacogenomics and the optimization of antipsychotic pharmacotherapy.

Albany Medical Center Department of Psychiatry Grand Rounds, February 2003.

Shirley KL. Psychiatric pharmacogenomics and the optimization of antipsychotic pharmacotherapy.

SUNY Upstate Syracuse, Department of Psychiatry and Neurology Grand Rounds, February 2003.

Shirley KL. Atypical antipsychotic-induced diabetes mellitus. CME Dinner presented to Syracuse County Clinic Psychiatrists, Syracuse, N.Y., February 2003.

Shirley KL. Managing HIV and psychotropic druginteractions. Continuing Medical Education Dinner presented to New York State Corrections medical personnel and infectious disease health care professionals, Albany, N.Y., February 2003.

ACP/Department of Pharmacy Practice

Triller DM and Clause SC. Medication health safety: Assessing patient risk of drug-related problems by level of medical care. International Society for Pharmacoepidemiology, 19th International Conference on Pharmacoepidemiology and the First International Conference on Risk Management, Philadelphia, Pa., August 2003.

Triller DM. Pharmacovigilance in a changing health care environment. Albany Law School, Albany, N.Y., October 2003.

Triller DM. Key points in management of chronic heart failure. New York State Council of HealthSystem Pharmacists, October 2003.

Triller DM. Improving medication management in home care. Saratoga County Department of Public Health, Saratoga Springs, N.Y., June 2003.

Shirley KL. Managing the emotional fallout of bioterrorism: Consequences of post-traumatic stress disorder. Pharmacy Practice Institute, Albany, N.Y., March 2003.

Shirley KL. Medical and economic outcomes of posttraumatic stress disorder. Ninth Annual Drug Utilization Review Conference, Albany N.Y., June 2003.

Shirley KL. Pharmacotherapy of agitation, delirium and dementia. 12th Annual Third Age Conference: Enhancing the Qualities of Life for Senior Persons with Developmental Disabilites, Albany, N.Y., May 2003.

Shirley KL and Anderson JL. Innovations in abnormal psychology education: Philosophy and pharmacology and understanding the troubled mind/ brain. College of Psychiatric and Neurologic Pharmacists Annual Meeting, Charleston, S.C., May 2003.

Shirley KL, Ferraioli A, David P and Balkosk V. Ethnic disparities in antipsychotic prescription patterns in an outpatient county mental health clinic.

College of Psychiatric and Neurologic Annual Meeting, Charleston, S.C., May 2003.

Darren M.Triller Clause SC and Triller DM. Grouping drug-related problems for failure analysis. American College of Clinical Pharmacy Annual Meeting, Atlanta, Ga., November 2003 [Encore].

Clause SC and Triller DM. Grouping drug-related problems for failure analysis. International Society for Pharmacoepidemiology, 19th International Conference on Pharmacoepidemiology and the First International Conference on Risk Management, Philadelphia, Pa., August 2003.

Triller DM and Clause SC. Medication health safety: Assessing patient risk of drug-related problems by level of medical care. American College of Clinical Pharmacy Annual Meeting, Atlanta, Ga., November 2003 [Encore].

Macary B. Weck Weck MB. Interviewing skills and business etiquette workshop. American Pharmacists Association Academy of Students of Pharmacy Midyear Regional Meeting, Las Vegas, Nev., November 2003.

Weck MB. Successful navigation through the pharmacy residency process. American Pharmacists Association Academy of Students of Pharmacy Midyear Regional Meeting, Las Vegas, Nev., November 2003.

Weck MB. Fight the flu: Use of influenza vaccine.

Albany College of Pharmacy CE Program, The common cold and the flu: Treatment and prevention, Albany N.Y., February 2003.

Weck MB. Pneumococcal vaccine: Another way to save lives. Albany College of Pharmacy CE Program, The common cold and the flu: Treatment and prevention, Albany N.Y., February 2003.

Weck MB. Emergency contraception: What you should know before they panic. Panel discussion for health and human service professionals, Rochester, N.Y., February 2003.

Weck MB. Access to emergency contraception: Testimony delivered to the New York State Assembly Committee on Health, Albany N.Y., January 2003.

Mario M. Zeolla Zeolla MM and Cerulli J. Impact of a community pharmacy-based women’s health education program. American College of Clinical Pharmacology Spring Forum, Palm Springs, Calif., April 2003.

Zeolla MM. Antiviral therapy for the prevention and treatment of influenza. Albany College of Pharmacy CE Program, The common cold and the flu: Treatment and prevention, Albany N.Y., February 2003.

Bold – Denotes ACP faculty collaborating on a project.

17 / PRESIDENT’S REPORT 2004

Sciences for ...

Understanding Providing health care is equal parts science and sociology, a mix of medicine and metaphysics.

To truly care for the human condition, it is important to understand the human experience, to have compassion for each individual and to understand the world in which they live.

“He had the uneasy manner of a man who is not among his own kind, and who has not seen enough of the world to feel that all people are in some sense his own kind.”

—Willa Cather (author; 1873-1947) That is the mission of the didactic and scholarly work of ACP’s Department of Humanities and Social Sciences. To foster better communication. Appreciation of diversity. Social awareness. Financial and legal responsibility. Moral and ethical decision making.

Department faculty have expertise in visual art, literature, anthropology, history, philosophy, religion, pharmacoeconomics, pharmacy administration and health systems administration. Their research encompasses a broad spectrum and sometimes is done in collaboration with faculty from other departments and institutions.

Through their own scholarly pursuits, department faculty bring to the classroom an expanded perspective on the values and attitudes associated with cultural and personal lifelong growth.

These are the tools, when combined with knowledge of the basic and pharmaceutical sciences, that mold not only a complete health care professional, but an enlightened citizen of the world.

PRESIDENT’S REPORT 2004 / 18

ACP/Department of Humanities and Social Sciences

“We're now in a period where we can't just accept that a particular drug is worth paying for; we have to prove it,” says Dr. Leon Cosler (right).

Studying the bottom line—the costs of drug delivery Prescription drugs have become one of the most important domestic issues for Americans. As the nation’s population ages, the debate over the cost, development and efficacy of drugs is a major component of most health care reform proposals.

Behind the scenes, pharmaceutical researchers like Leon Cosler play a critical part in this high-profile subject.

An Assistant Professor of Pharmacoeconomics in the Department of Humanities and Social Sciences, Dr. Cosler (Ph.D., Union College) conducts research on the benefits of drugs and their cost effectiveness. Much of Dr. Cosler’s research has focused on neutropenia, a toxicity associated with cancer chemotherapy, and the drugs that are used to treat it.

“We’re now in a period where we can’t just accept that a particular drug is worth paying for; we have to prove it,” Dr. Cosler said.

“I think there is a lot of room to inform providers and the public about when is the best time economically to use a given product.”

His study is done in collaboration with the Awareness of Neutropenia in Chemotherapy, a small study group formed

expressly to evaluate the management of chemotherapy toxicities. The group is funded by a multi-milliondollar unrestricted grant from pharmaceutical company Amgen, secured by Dr. Gary Lyman, a nationally recognized oncologist.

“I’m hoping that the tools, processes and evaluation we use will be able to be applied to other drugs in similar situations,” Dr. Cosler said. “There are a variety of economic tools available to help doctors, hospitals, HMOs and the federal government (which administers Medicare) to make more informed decisions about which drugs to use.”

Dr. Cosler is also the Chair of an American Pharmacists Association committee that this year created a monograph – or continuing education document – that provides pharmacists with a thorough overview of the changing Medicare drug benefits.

19 / PRESIDENT’S REPORT 2004

Stepping into a cultural divide Boston’s Chinatown was a place most people wanted to avoid in the summer of 2003. Not Erika Muse.

For Dr. Muse (Ph.D., State University of New York at Albany), it was the perfect time – amid the international scare over Severe Acute Respiratory Syndrome, or SARS – and the perfect place to conduct research into the culture clash between Western medicine and traditional Chinese methods of healing and health maintenance.

What she found was a normally bustling community that had fallen eerily quiet, petrified by the outbreak of the potentially deadly disease. Dr. Muse found the disease had severely divided the Chinese community, primarily along economic lines.

“This research looks at ethnic divisions, which of course have socioeconomic implications,” she said.

An Assistant Professor in the Department of Humanities and Social Sciences, Dr. Muse gathered information from 42 Chinatown residents over two weeks.

Along with ethnic and socioeconomic findings related to SARS, Dr. Muse also discovered an immigrant population struggling to hold onto a deeply rooted heritage while also

assimilating into – or simply being swept up by – a powerful new culture that ran counter to intuitive practices handed down through the centuries.

Ninety-one percent of her subjects at least moderately agreed that they use both traditional Chinese and Western medicine; 94 percent at least moderately agreed that they were happy with their Western doctor. This signified, according to Dr. Muse, a growing belief that it is possible to have a harmonious meeting of East and West – yung zai yi qi, a balance of the two philosophies.

Dr. Muse’s research is unique among the American Chinese population because of use of interviews and participant observation. Her findings, which she will publish in an anthropological journal, contribute significantly to information available on ethnicity, cultural identity and health in the United States.

At ACP, Dr. Muse’s work will be incorporated into Humanities courses to help students better understand how to serve a diverse population.

Dr. Erika Muse (left) conducts unique research on the American Chinese population that will contribute significantly to information available on ethnicity, cultural identity and health.

PRESIDENT’S REPORT 2004 / 20

ACP/Department of Humanities and Social Sciences

Publications Kenneth J. Blume Blume, KJ. Instructor’s Test Item File for Paul Boyer et al, The Enduring Vision: A History of the American People, 5th ed., Boston: Houghton Mifflin, 2003.

Eric H. Hobson Farragon JJ, Waite NM, Hobson EH, Seoldo N, VanAmburg JA and Migden H. Improving aspirin use in a primary care diabetic population. Pharmacotherapy 23(1):73-79, 2003.

Ray Chandrasekara Chandrasekara, R. Emblems of honor, emblems of desire: The Hikayat Hang Tuah. Proceedings of Hawaii International Conference on Arts and Humanities. January 2003.

Waite NM and Hobson EH. The flu review. New York State Office for the Aging, Adult Immunization Campaign. A patient education Web site: http://agingwell.state.ny.us.flureview/index.htm.

Leon E. Cosler Cosler LE. Pharmacoeconomics and considerations for injectable products: Focus on colonystimulating factors. Journal of Managed Care Pharmacy March-April; 9(2 Suppl):4-5, 2003.

Wagner AK, Soumerai SB, Zhang F, Mah C, Simoni-Wastila L, Cosler LE, Fanning T, Gallagher P and Ross-Degnan D. Effects of state surveillance on new post-hospitalization benzodiazepine use. International Journal for Quality in Health Care Oct.; 15(5):423-31, 2003.

Turner BJ, Laine C, Cosler LE and Hauck WW. Relationship of gender, depression and health care delivery with antiretroviral adherence in HIV-infected drug users. Journal of General Internal Medicine April; 18(4): 248-57, 2003.

Waite NM and Hobson EH. The pneumonia review. New York State Office for the Aging, Adult Immunization Campaign. A patient education Web site: http://agingwell.state.ny.us/flu/ pneumonia_review/index.htm.

Waite NM and Hobson EH. The vaccination review. New York State Office for the Aging, Adult Immunization Campaign. A patient education Web site: http://agingwell.state.ny.us/flu/ vaccination_review/index.htm.

Elisabeth L. Vines Vines EL. Review essay of A Companion to the works of Heinrich Heine,” ed. by Roger F. Cook.

Camden House 2002, Choice, March 2003.

Bold – Denotes ACP faculty collaborating on a project.

Angela C. Dominelli Dominelli AC. Web surveys: Benefits and consideration. Clinical Research and Regulatory Affairs.

20(4): 419-426, fall 2003.

Kevin M. Hickey Hickey KM. Professing passion: Review essay of Marjorie Garber’s Academic Instincts. The Vanguard, 23(2), winter 2003.

Hickey KM. Central Africa. The Literature of Travel and Exploration: An Encyclopedia. London, Fitzroy Dearborn, I: 208-210, 2003.

21 / PRESIDENT’S REPORT 2004

Sciences for ...

Learning A complete education is not found in a classroom or a book. It requires more than absorption of information.

It takes opportunities to apply that information, to explore for one’s self the paradigms and mysteries of acquired knowledge.

“I hear and I forget.

I see and I remember.

I do and I understand.”

—Confucius (philosopher; 551-479 B.C.)

PRESIDENT’S REPORT 2004 / 22

In its efforts to enhance these opportunities, ACP assists students in developing research projects that broaden their academic and professional interests. The Summer Research Internship is an eightweek program that provides housing and a $2,000 stipend or three credit hours of independent research.

Selection is based on grade-point average and offers opportunities to pursue laboratory, clinical and other research with faculty. A total of 66 summer stipends have been awarded over the last six years; 12 students were accepted for Summer 2004.

Over the last four years, students co-authored 25 publications related to their summer research and have given five presentations at local, national and international meetings, including the annual Student Research Conference at West Virginia University.

ACP also partners with Albany High School and the City of Albany to offer a select group of seniors-to-be research exposure.

The Summer High School Enrichment Program seeks to cultivate in these teen-agers an interest in a career in science.

ACP/Student Research

Helping to stop the bleeding As part of the 2003 ACP Summer Research Internship, Lauren DeRitter and Melissa Cloonan embarked on a blood coagulation study under the guidance of Shaker Mousa, Ph.D., Director of the Pharmaceutical Research Institute. The students worked independently, but both projects involved testing elements that decrease clotting.

DeRitter, a third-year Doctor of Pharmacy student, focused on how natural products may decrease the time it takes blood to clot.

“I tested flavanoids that exist in red wine and in most red and purple vegetables and fruits, including resveratrol as well as garlic extract and its ingredients,” she explained.

“The goal was to see if resveratrol helps heparin – an anticoagulant drug – decrease clotting.”

DeRitter found several active natural products – including flavones, isoflavones, garlic, tea extracts and ingredients containing sulfur and selenium – that can reduce clot formation. Cloonan, a third-year student in the Bachelor of Science in Pharmaceutical Sciences program, tested how prescription drugs impact coagulation.

“We found that efficacy is based on the molecular weight of heparin – the greater the weight of the drug, the more effective it was in fighting coagulation,” she said.

Cloonan, who plans to attend medical school after ACP, also researched coagulation’s effect on cancer, finding a link that suggests that the spread of cancer can be slowed or stopped by preventing coagulation. Dr. Mousa, whose own research focuses in part on clotting – or thrombosis – said both students developed important findings.

“It can help us to find a natural product that can solve the problem by itself, or a natural product that can be used to make an existing medicine better and safer,” he said.

Melissa Cloonan (left) and Lauren DeRitter (right) developed important findings to assist Dr. Shaker Mousa's research into blood coagulation.

23 / PRESIDENT’S REPORT 2004

Rewarding possibilities await participants in ACP's Summer High School Enrichment Program. The College is pleased to help guide Albany High School students such as 2003 participants Jeffrey Ryan-Pepper and Elizabeth Fabian (left) in a direction that will make the world a healthier place.

Researching an exciting future While many of their friends are enjoying a typical summer of fun and sun, a small group of Albany High School students takes a different kind of break from their schoolwork each year.

These students participate in ACP’s annual Summer High School Enrichment Program. A partnership with the City of Albany, the six-week program was created in 1999 to excite seniors-to-be about the possibilities available to them in the sciences and medicine, and to instill in them the wonder of the exponential possibilities that exist in the world of research.

From 1999-2003, 38 students participated; three went on to enroll at ACP and all followed science-related paths after high school.

The program also was a catalyst for Albany Mayor Jerry Jennings’ Summer Institute for Career Exploration, new in 2004.

Along with the ACP partnership, the program now includes exposure to professions such as accounting, law and architecture.

At ACP, students spend three days a week involved in basic and clinical research, one

PRESIDENT’S REPORT 2004 / 24

day conducting research literature reviews related to their research experience and one day on relevant field trips.

Capital Region facilities visited have included Albany Molecular Research Inc., Organichem Corp., Albany Medical Center, Lindsay Drug Co., Albany County Nursing Home, a CVS Pharmacy and AxelrodWadsworth Laboratories, among others.

The students also are introduced to a college campus, many for the first time. This is valuable experience as they begin to move seriously toward decisions about their future.

ACP provides a launching pad for these students. Rewarding academic and career possibilities await them, and the College is pleased to help guide them in a direction that ultimately will make the world a healthier place.

OFFICE OF GRANTS ADMINISTRATION

M. Elyse Wheeler, Ph.D., MT (ASCP) Associate Dean of Graduate and Extension Programs (o) 518.445.7232 wheelere@acp.edu

Robert M. Levin, Ph.D. Director of Research (o) 518.445.7306 levinr@acp.edu

PHARMACEUTICAL RESEARCH INSTITUTE

Shaker A. Mousa, Ph.D., M.B.A Director (o) 518.445.7397 mousas@acp.edu

OFFICE OF COMMUNICATIONS

Ron Lesko Director (o) 518.445.7394 leskor@acp.edu

25 / PRESIDENT’S REPORT 2004

Albany College of Pharmacy Balance Sheet

ASSETS Cash and Cash Equivalents Investments Other Assets Accounts Receivable-Students Receivables-Government Entities Other Receivables Pledges Receivable Student Loans Receivable Agency Funds Property, Plant & Equipment - Net Total Assets LIABILITIES AND NET ASSETS Liabilities Accounts payable and accrued liabilities Deferred income and deposits U.S. government grants refundable Bonds Payable Capital Lease Obligation-net Land Lease Payable Expected Post Retirement Benefit Obligation Deposits held in custody for others Total Liabilities Net Assets UNRESTRICTED: Unrestricted Plant Fund Quasi-Endowment Funds Total Unrestricted TEMPORARILY RESTRICTED: Unexpended funds received for restricted purposes College matching contribution to student loans Total Restricted PERMANENTLY RESTRICTED: True-Endowment Funds O’Brien Loan Fund Total Permanently Restricted Total Net Assets Total Liabilities and Net Assets

PRESIDENT’S REPORT 2004 / 26

June 30, 2003 $2,568,360 6,642,105 730,015 215,402 198,653 487,005 1,135,609 1,822,720 757,596 21,274,043 $35,831,508

$275,347 953,440 1,850,223 3,130,000 7,772,222 229,598 715,683 757,596 $15,684,109

$990,177 11,363,263 3,524,779 $15,878,219

$200,674 285,420 $486,094

$3,752,122 30,964 $3,783,086 $20,147,399 $35,831,508

ACP/Financial Statements

Revenues Student Tuition and Fees (71.74%) Government Contracts and Grants (6.49%) Gifts and Pledges (9.21%) Investment Income (0.25%) Postgraduate Education (2.68%) Other Sources (2.34%) Auxiliary Enterprises (7.29%)

Expenditures

General Administration (19.23%) Research (8.50%) Student Financial Aid (10.30%)

Physical Plant (7.90%) Institutional Advancement (4.18%) Postgraduate Education (1.97%) Instruction/Student Services (47.92%)

27 / PRESIDENT’S REPORT 2004

Board of Trustees OFFICERS

Kandyce J. Daley ’74, Chair Zachary I. Hanan ’63, Vice Chair Michael F. Bette, Treasurer Robert F. McGaugh ’57, Secretary TRUSTEES

Allen Barnett Murray R. Blair, Jr. James E. Bollinger ’58 Robert S. Busch Richard A. Cognetti ’69 Richard H. Daffner ’63 Francis J. DiLascia ’54 Roger H. Hull David M. Kile ’74 Joseph M. Lapetina Rita E. Leighton ’86 Thomas O. Maggs Richard G. Robison ’52 Gary J. Salamido ’86 John M. Woychick CHAIRMAN EMERITUS

Alfred J. Collins, Jr. ’53 TRUSTEES EMERITI

Rudolph H. Blythe ’31 Kenneth M. Nirenberg

PRESIDENT’S REPORT 2004 / 28

“The important thing is not to stop questioning. Curiosity has its own reason for existing. One cannot help but be in awe when he contemplates the mysteries of eternity, of life, of the marvelous structure of reality. It is enough if one tries merely to comprehend a little of this mystery every day.”

—Albert Einstein (physicist, mathematician; 1879-1955)

ACP 106 New Scotland Avenue Albany, NY 12208-3492 1-888-203-8010 www.acp.edu